1. Short title This Act may be cited as the We Protect American Investment in Drugs Act or the We PAID Act . 2. Findings Congress finds the following: (1) In addition to spurring economic growth, the National Institutes of Health supports some of the most significant breakthroughs in biomedical innovation, including some that are commercialized into new pharmaceutical products. (2) The National Institutes of Health funding contributed, either directly or indirectly, to the development of all 210 new molecular entities approved by the Food and Drug Administration between 2010 and 2016, according to an analysis published in the Proceedings of the National Academy of Sciences. (3) In fiscal year 2019, Congress provided $39,100,000,000 in funding for the National Institutes of Health. (4) According to a Kaiser Family Foundation health tracking poll in February 2019— (A) nearly 80 percent of people in the United States say that the cost of prescription drugs is unreasonable and only 25 percent trust pharmaceutical companies to price their products fairly; and (B) one-fourth of people in the United States say it is difficult to afford their prescription drugs, and 3 in 10 say they have not taken their medications as prescribed due to costs. (5) According to a September 2018 report from the AARP— (A) between 2016 and 2017, retail prices for 267 widely used brand name prescription drugs increased by 8.4 percent after 5 straight years of double-digit average annual price increases; (B) brand name drug prices increased 4 times faster than general inflation in 2017